TARS Just Ran 16% Into the Ceiling That's Capped It All Year — $80 Decides Whether the Breakout Lives or the Trap Springs

Tarsus Pharmaceuticals broke out of a month-long basing range and ripped roughly 16% higher in 20 sessions, and then on the first red day it pulled straight back toward the exact shelf it just escaped. At a quote near $81 — off a session low of $80.81 after opening at $80.89 and tagging $83.34 — the stock is doing something more interesting than a biotech pop: it is staging the first retest of the level that determines whether this is a durable re-rating or a dead-cat climb into old supply.

Here is the sticky part nobody on the tape is talking about. Tarsus is now ~11% below its 52-week high of $91.53, but that high was set months ago, before the street's best sales quarter on record. In other words, the chart has rallied hard on better-than-expected numbers and still hasn't made it back to the ceiling sellers defended all year. That gap between what the business just did and where the stock sits is the whole setup.

The breakout came from somewhere real

Let's put the move in context. The 20-day gain of roughly +16% started from a base near $70, where Tarsus had been compressing for weeks — and crucially, where the 50-day and 200-day moving averages had converged around $67–69. Reclaiming that confluence after being above neither average is what turns a bounce into a structural change: it puts the average investor's cost basis underneath price again instead of overhead.

The catalyst behind the run was concrete. On August 6, Tarsus reported record second-quarter net product sales of $173.9 million for XDEMVY and raised full-year 2026 guidance to $685–705 million, while posting a net loss of $18.6 million. That followed a first quarter where XDEMVY sales grew more than 85% year over year and management framed peak sales potential at more than $2 billion. This is not a rumor trade — it is a company in the middle of a visible top-line acceleration.

The product economics matter to the chart, because this is the first and only FDA-approved therapy for Demodex blepharitis, an eyelid disease affecting roughly 25 million U.S. eye-care patients. Tarsus also banked an international data point in March, when Chinese regulators approved the drug, triggering a $15 million milestone payment. Growth molecules with a real addressable population are why traders pay up for the base, and why the retest matters at all.

Today's pullback is digestion, unless the shelf breaks

The most recent session shows why the setup is alive rather than already resolved. It was a low-turnover pullback — roughly 1% of shares turning over — with retail money the marginal net seller while block and large orders stayed close to flat. That is the fingerprint of profit-taking on a double-digit month, not a coordinated distribution event. A crowded exit would show heavy institutional outflow on expanding volume; this shows a quiet cooling-off.

That reading is what separates a pullback from a rollover. The stock is ~20% extended above its 50-day average after the run, so some give-back is normal — even healthy — as long as the first retest holds. And because today's flush stopped at $80.81 and price is back above $81, the shelf that matters is right here: round $80 plus the session low. That level has market memory now — it is where buyers stepped in on the first meaningful red day after a breakout, not a number invented from today's quote.

What changes on either side:

• Above $82.77 and the recent high of $83.34 — the pullback is just a tap on the brakes. A close back above that puts the next leg in play toward the $85–86 zone, and the real prize is the $90 wall and the $91.53 high overhead, the supply that capped Tarsus all year.
• Below $80 — the breakout shelf is giving way. Price then has thin support until the low-$70s, and a move back under the $67–69 moving-average confluence would confirm a failed breakout that traps everyone who bought the run.

The asymmetry is the point. Chasing here is the wrong move — price is extended and the best entry has passed. But a hold of $80 through another retest sets up a run at the 52-week high roughly $10 above, while a close under the shelf risks a trip back toward the low-$70s. The reward path is meaningfully larger than the distance to the invalidating level, provided you respect the line rather than the narrative.

The trade map

Scenario	Trigger	Path	Invalidation	Horizon
Breakout resumes	Reclaim and hold $82.77, clear $83.34 on participation	Rally into $85–86, then the $90 wall / $91.53	Close back below $80	Multiweek swing
Breakout fails	Daily close under $80, losing the retest	Air pocket to low-$70s, then the $67–69 MA test	Reclaim of $80 needed to stop it	Days to weeks

The verdict

Tarsus has given traders a genuine contest: a breakout fueled by its best-reported quarter in history, pulling back to a fresh, earned shelf at $80 while still sitting 11% below the ceiling it has respected all year. What the market is missing is that the stock is repricing on the fundamentals and the chart hasn't caught up — yet.

Hold $80 through the next retest and the empty air toward the $90 wall — and with it the 52-week high at $91.53 — comes into play. Lose $80 on a close and the breakout is broken, and the same buyers who fueled the 16% run become the inventory that caps every bounce on the way back down. Everything now runs through $80.

Data as of the latest session reflected in the market snapshot (Sept. 10 close; quote ~$81). Technical levels from the assigned market-data service; fundamentals from company releases and filings.